It is well known that allo-reactive T-cells play a crucial role in graft-versus-leukemia and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Alloreactive CD4 + T-cells can mediate direct cytolysis, but may also stimulate production of Since PTK2B has also been described as antibody target, we here investigated whether a coordinated T-and B-cell response against PTK2B was induced.
ABSTRACT
It is well known that allo-reactive T-cells play a crucial role in graft-versus-leukemia and graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Alloreactive CD4
+ T-cells can mediate direct cytolysis, but may also stimulate production of IgG antibodies as helper cells. Immune complexes may subsequently be processed and presented by professional antigen presenting cells and stimulate induction of specific CD8 + T-cells. As such, proteins targeted in coordinated T-and B-cell responses may represent a class of immunodominant antigens in clinical responses after alloSCT. We previously identified LB-PTK2B-1T as HLA class II restricted polymorphic antigen in a patient treated with donor lymphocyte infusion for relapsed chronic myeloid leukemia after HLAmatched alloSCT. Since PTK2B has also been described as antibody target, we here investigated whether a coordinated T-and B-cell response against PTK2B was induced.
Patient serum before and after alloSCT and DLI was screened for antibodies, and we indeed observed development of a humoral immune response against PTK2B. Antibodies against PTK2B were only found after DLI and, in contrast to the CD4 + T-cells, recognized a monomorphic region of the protein. To our knowledge this is the first description of a coordinated allo-reactive CD4 + T-cell and auto-reactive antibody response against an autosomal antigen.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (alloSCT) is often the only therapeutic option for patients with hematological malignancies. During this treatment patient hematopoiesis is eradicated by high-dose radio-/chemotherapy and the patient is rescued by infusion of hematopoietic stem cells of an (HLA-matched) donor. 1 While in the beginnings of alloSCT infusion of donor hematopoiesis was solely meant to rescue the patient from the otherwise lethal radio-/chemotherapy, it is known by now that its beneficial effect is actually mediated by an immune response of donor cells against residual malignant cells of the patient, the so-called graft-versus-leukemia (GvL) effect. 2 The same immune reaction, however, can also be directed against healthy non-hematopoietic tissues of the patient causing detrimental graft-versus-host disease (GvHD). 6 , and they are also known to deliver essential signals for B-cells to produce IgG antibodies. 7 Although the capacity of CD4 + T-cells to stimulate production of antibodies is well-known, and induction of autoand allo-reactive antibodies after HLA-matched alloSCT has been demonstrated by various studies [8] [9] [10] [11] [12] [13] [14] [15] , the link between CD4 + T-and B-cell immunity after alloSCT has only been demonstrated for DDX3Y, a male specific antigen encoded on the Y-chromosome. 16, 17 We previously identified 5 HLA class II restricted polymorphic antigens as targets for alloreactive CD4 + T-cells in a patient with relapsed chronic myeloid leukemia who responded to donor lymphocyte infusion (DLI) after HLA-matched alloSCT. 18, 19 One of these antigens has been shown to be derived from human PTK2B, which is a member of the focal adhesion kinase family of proteins. PTK2B, also known as PYK2 or RAFTK, has previously been described as target for antibodies in 3 of 19 patients treated with DLI for relapsed CML after HLA-matched alloSCT. 10 It has, however, not been addressed whether these antibodies were allo-or auto-reactive and whether T-cells specific for PTK2B were induced in these patients.
We here investigated whether allo-reactive CD4 + T-cells against PTK2B exerted helper function in vitro and whether a coordinated B-cell response was induced in vivo. Alloreactive CD4 + T-cells against LB-PTK2B-1T were shown to induce DC maturation and Bcell activation in vitro. Moreover, we showed in vivo induction of a humoral immune response against PTK2B after DLI. This antibody response was mapped to a small nonpolymorphic region of the protein.
In conclusion, this is the first report demonstrating induction of a coordinated allo T-cell and auto B-cell response against an autosomal antigen after alloSCT.
METHODS

Antigen presentation assays
EBV-LCL were loaded with 1 µg/mL of synthetic peptides in IMDM with 2% FCS and incubated for 2 hours at 37°C. Cells were washed twice and plated at 30.000 cells/well in a 96-wells plate. Effector cells were added at 5000 T-cells/well. After overnight coincubation IFN-γ production was measured by ELISA (Sanquin, Burton upon Trent, UK)
following instructions of the manufacturer.
Helper function assays
To induce maturation of dendritic cells (DC), CD4 + T-cell clones and immature DC were seeded in a 1:1 ratio in a 24-wells plate. After 4 days of co-incubation, cells were harvested, washed and stained with antibodies for FACS analysis. For induction of B-cell activation, CD4 + T-cell clones and isolated B-cells were seeded in a 1:1 ratio and after 2 days of coincubation, cells were harvested, washed and stained for FACS analysis. BSA, and subsequently incubated with diluted (1:40) serum samples overnight at 4°C.
Western blot analysis
Subsequently, the membrane was incubated with biotinylated anti-human IgG and streptavidin-QDots 625 (Invitrogen) for one hour each and visualized under UV illumination.
Suspension bead array
The suspension bead array was performed as previously described. 21 Purified proteins ( and 1% bovine serum albumin (BSA) for 1 hour prior to incubation with the proteincoupled bead mix at room temperature on a shaker for 1 hour. In specific blocking experiments, serum samples were pre-absorbed with purified recombinant proteins at 0.5 or 2.0 µg/mL in PVX and 1% BSA. Beads were washed and incubated for another hour with PE-labeled anti-human IgG, and fluorescence was measured on a Bioplex-100 (BioRad).
RT-PCR
Clonotypic RT-PCR was designed with a forward primer specific for the variable T-cell receptor β-chain and a reverse primer specific for the CDR3 region of clone 78. Expansion of the PCR product was followed by measuring fluorescence of the DNA-intercalating fluorophore EvaGreen (Biotium, San Francisco, CA), and specificity of the PCR product was confirmed by melting curve analysis.
RESULTS AND DISCUSSION
LB-PTK2B-1T specific CD4 + T-cells can provide specific help
LB-PTK2B-1T specific CD4 + T-cell clone 78 has been isolated 5 weeks after DLI based on expression of activation marker HLA-DR on bone marrow cells from a patient with relapsed CML after HLA-matched alloSCT. 19 The specificity of this T-cell clone was demonstrated by IFN-γ production upon stimulation with patient, but not donor, EBV-LCL as well as donor EBV-LCL loaded with LB-PTK2B-1T peptide ( Figure 1A ). To investigate in vivo dynamics of the T-cell response, we developed a clonotypic PCR for the CDR3 region of clone 78 and detected a specific PCR product in patient PBMC 9 weeks after DLI (Ct = 36), but not in patient samples collected before alloSCT or prior to DLI and in a donor sample, whereas the PBGD housekeeping gene was similarly expressed in all samples (Ct = 25-27) (data not shown).
These data demonstrate that LB-PTK2B-1T specific CD4 reactivity against PTK2B could be measured by both methods. Whereas antibody reactivity against CMV or EBV antigens was detectable in all serum samples, reactivity against PTK2B specifically evolved after DLI, and was not found before alloSCT or prior to DLI.
Antibody reactivity against PTK2B after DLI could not be explained by an overall increase in antibodies after immune recovery, as witnessed by decreased binding of antibodies to EBV-derived antigen EBNA1 and lack of reactivity against other cellular proteins on Western blot. To further determine the immunogenic region of PTK2B, we produced partially overlapping recombinant protein fragments and mapping for recognition sites showed that antibody reactivity was directed against the C-terminal part of PTK2B (PTK2B-B; Figure 2C ). Further fragmentation of the C-terminus of PTK2B revealed that the antibody epitope was located in a non-polymorphic region between amino acids (aa)
843 -967 (PTK2B-4; Figure 2D ), whereas the polymorphic T-cell epitope is located between aa 791 -800. By sequencing PTK2B cDNA of patient and donor, we confirmed that no differences were present within this region (data not shown), illustrating that the humoral immune response after DLI consisted of auto-antibodies against PTK2B.
CONCLUDING REMARKS
In this report, we demonstrate induction of a coordinated allo CD4 + T-and auto B-cell response against autosomal antigen PTK2B after alloSCT. In contrast to the coordinated B- In the situation of DLI for leukemic relapse it is conceivable that release of cytosolic contents due to tissue damage mediated by activated allogeneic T-cells may have triggered a break in B-cell tolerance and production of auto-antibodies against intracellular selfantigens. 10 Although antibodies against intracellular antigens are not expected to mediate direct cytolysis, immune complexes may be formed, which can be efficiently processed and presented by professional antigen presenting cells, thereby stimulating induction or amplification of specific T-cell responses. [26] [27] [28] As such, proteins targeted in coordinated Tand B-cell responses may represent a class of immunodominant antigens in clinical responses after alloSCT. However, it should be noted that, although simultaneous development of T-and B-cell responses against the same protein is suggestive for cognate T-cell help, non-cognate T-cell responses and direct stimulation by TLR-ligands cannot be ruled out and should also be considered as stimulators for auto-reactive B-cells.
In conclusion, our data demonstrate development of a coordinated CD4 + T-and B-cell response against autosomal antigen PTK2B. Based on this patient case, it is tempting to speculate that allo-reactive CD4 + T-cells as administered by DLI may break B-cell tolerance and stimulate development of auto-antibodies after alloSCT. 
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Production of recombinant proteins
Gene sequences encoding full length and partial PTK2B proteins were cloned into a
Gateway vector with a N-terminal His-tag (pDEST17; Invitrogen) according to instructions of the manufacturer. The identity of the constructs was verified by DNA sequencing.
Recombinant proteins were obtained from bacterial cultures after addition of 0.4 mM IPTG for 4 hrs by isolation of inclusion bodies as described by Palmer et al. 20 with minor modifications.
Suspension bead array
The suspension bead array was performed as previously described by Schwenk et al. 21 Purified proteins (20 µg) were coupled to carboxylated beads (Bio-Rad Laboratories B.V., Veenendaal, The Netherlands) according to manufacturers' instructions. Diluted serum samples (1:100 and 1:300) were pre-absorbed with 0.5% (w/v) polyvinylalcohol and 0.8% (w/v) polyvinylpyrrolidone (Sigma) (PVX) and 1% bovine serum albumin (BSA) for 1 hour prior to incubation with the protein-coupled bead mix at room temperature on a shaker for 1 hour. In specific blocking experiments, serum samples were pre-absorbed with purified recombinant proteins at 0.5 or 2.0 µg/mL in PVX and 1% BSA. Beads were washed and incubated for another hour with PE-labeled anti-human IgG, and fluorescence was measured on a Bioplex-100 (BioRad). primers. RT-PCR conditions were as follows: 10 min at 95ºC, followed by 50 cycles of 15 sec for denaturing at 95ºC, 30 sec of annealing at 65ºC, and 20 sec extension at 72ºC, and final elongation for 5 min at 72ºC. After amplification, specificity of the PCR products was confirmed by melting curve analysis.
RT-PCR
